The fight against chronic metabolic disease is shifting fast. In the U.S., millions of patients who struggle to afford life-changing treatments like Ozempic may finally see a breakthrough, as Novo Nordisk opens new, cheaper access points for those without insurance.

And just as the affordability conversation takes center stage, another milestone arrives: the FDA has given its nod to GLP-1 receptor targeting for fatty liver disease, approving Novo Nordisk’s Wegovy as only the second-ever treatment for MASH.

What does this mean for patients, healthcare systems, and the future of metabolic medicine?

Join Dan Koh and Audrey Siek as they unpack as they break down what this means for Novo’s growth trajectory, how it impacts competitors, and why the GLP-1 category is fast becoming one of the most important stories in healthcare investing.

The fight against chronic metabolic disease is shifting fast. In the U.S., millions of patients who struggle to afford life-changing treatments like Ozempic may finally see a breakthrough, as Novo Nordisk opens new, cheaper access points for those without insurance.
And just as the affordability conversation takes center stage, another milestone arrives: the FDA has given its nod to GLP-1 receptor targeting for fatty liver disease, approving Novo Nordisk&rsquo;s Wegovy as only the second-ever treatment for MASH.
What does this mean for patients, healthcare systems, and the future of metabolic medicine?
Join&nbsp;Dan Koh and Audrey Siek as they unpack as they break down what this means for Novo&rsquo;s growth trajectory, how it impacts competitors, and why the GLP-1 category is fast becoming one of the most important stories in healthcare investing.

From current affairs and social issues to lifestyle trends and community voices, each segment offers a different lens on what’s happening — and what’s worth your attention.

Start your day with the stories shaping Singapore — and your place in it.

Join Neil Humphreys and Audrey Siek as they cover the biggest headlines, trending topics, and everyday conversations, unpacked through fresh perspectives, expert insights, and engaging discussion. From current affairs and social issues to lifestyle trends and community voices, each segment offers a different lens on what’s happening — and what’s worth your attention.

And it’s not just talk — it’s your voice. Through polls, messages, and live call-ins, listeners are part of the conversation, sharing their views and shaping the discussion in real time. With a mix of clarity, curiosity, and personality, Let’s Talk, Singapore keeps you informed, connected, and ready for the day ahead.

Start your day with the stories shaping Singapore &mdash; and your place in it.
Join Neil Humphreys and Audrey Siek as they cover the biggest headlines, trending topics, and everyday conversations, unpacked through fresh perspectives, expert insights, and engaging discussion. From current affairs and social issues to lifestyle trends and community voices, each segment offers a different lens on what&rsquo;s happening &mdash; and what&rsquo;s worth your attention.
And it&rsquo;s not just talk &mdash; it&rsquo;s your voice. Through polls, messages, and live call-ins, listeners are part of the conversation, sharing their views and shaping the discussion in real time. With a mix of clarity, curiosity, and personality, Let&rsquo;s Talk, Singapore keeps you informed, connected, and ready for the day ahead.